A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors
Purpose
The purpose of this study is to evaluate safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-75098 alone and in combination with BGB-43395 and fulvestrant in participants with advanced solid tumors.
Condition
- Advanced Solid Tumor
Eligibility
- Eligible Ages
- Over 18 Years
- Eligible Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Participants must have measurable disease as assessed by RECIST v1.1. - Participants must have a stable Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1. - Participants must have adequate organ function. - Dose Escalation Part A: Participants with histologically or cytologically confirmed advanced, metastatic, or unresectable solid tumors potentially associated with cyclin-dependent kinase 2 (CDK2) dependency. Participants should have received prior treatment with available standard-of-care (SOC) systemic therapies for advanced/metastatic disease, or for whom standard therapy is not available or not tolerated. - Dose Escalation Part B: Patients with histologically or cytologically confirmed advanced, metastatic, or unresectable solid tumors who have received ≥ 1 prior line of systemic therapy in the metastatic setting. - Dose Expansion Cohort 1: Participants with histologically or cytologically confirmed advanced, metastatic, or unresectable CDK4/6 inhibitor-progressed solid tumors. - Dose Expansion Cohort 2: Participants with advanced solid tumors. Participants with primary platinum refractory disease are not eligible. Participants should have received ≥ 1 line of platinum-containing chemotherapy and ≤ 4 prior therapeutic regimens in the advanced/metastatic setting.
Exclusion Criteria
- For all cohorts: Prior therapy selectively targeting CDK2 inhibition or degradation. - For combination cohorts: Prior therapy selectively targeting CDK4. Prior CDK4/6 inhibitor standard of care therapy is permitted and required in local regions where it is approved and available. - Participants with active leptomeningeal disease or uncontrolled, untreated brain metastasis. NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Study Design
- Phase
- Phase 1
- Study Type
- Interventional
- Allocation
- Non-Randomized
- Intervention Model
- Sequential Assignment
- Primary Purpose
- Treatment
- Masking
- None (Open Label)
Arm Groups
| Arm | Description | Assigned Intervention |
|---|---|---|
|
Experimental Phase 1a, Part A: Dose Escalation, BG-75098 Monotherapy |
Sequential cohorts of increasing dose levels of BG-75098 will be evaluated as monotherapy. |
|
|
Experimental Phase 1a, Part B: Dose Escalation, BG-75098 Combination |
Sequential cohorts of increasing dose levels of BG-75098 will be evaluated in combination with BGB-43395 and fulvestrant. |
|
|
Experimental Phase 1b, Cohort 1: Dose Expansion, BG-75098 Combination |
Participants will receive BG-75098 at the recommended dose level from Phase 1a in combination with BGB-43395 and fulvestrant. |
|
|
Experimental Phase 1b, Cohort 2: Dose Expansion, BG-75098 Monotherapy |
Participants will receive BG-75098 as monotherapy at the recommended dose level from Phase 1a. |
|
Recruiting Locations
University of Alabama At Birmingham Hospital
Birmingham, Alabama 35294-0004
Birmingham, Alabama 35294-0004
More Details
- Status
- Recruiting
- Sponsor
- BeOne Medicines
Detailed Description
This study will be conducted in 2 phases: Phase 1a Dose Escalation and Phase 1b Dose Expansion.